HuR stabilizes HTT mRNA via interacting with its exon 11 in a mutant HTT-dependent manner

References

• TheHuntington’sDiseaseCollaborativeResearchGroup. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–983.
   PubMed Web of Science ®Google Scholar
• Rubinsztein DC, Carmichael J. Huntington’s disease: molecular basis of neurodegeneration. Expert Rev Mol Med. 2003;5:1–21.
   PubMedGoogle Scholar
• Feng X, Luo S, Lu B. Conformation polymorphism of polyglutamine proteins. Trends Biochem Sci. 2018;43:424–435.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lebron E, Denovan-Wright EM, Nash K, et al. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther. 2005;12:618–633.
   PubMed Web of Science ®Google Scholar
• Harper SQ, Staber PD, He X, et al. RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc Natl Acad Sci U S A. 2005;102:5820–5825.
   PubMed Web of Science ®Google Scholar
• DiFiglia M, Sena-Esteves M, Chase K, et al. Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc Natl Acad Sci U S A. 2007;104:17204–17209.
   PubMed Web of Science ®Google Scholar
• Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031–1044.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting Huntingtin expression in patients with Huntington’s disease. N Engl J Med. 2019;380:2307–2316.
   PubMed Web of Science ®Google Scholar
• Chung DW, Rudnicki DD, Yu L, et al. A natural antisense transcript at the Huntington’s disease repeat locus regulates HTT expression. Hum Mol Genet. 2011;20:3467–3477.
   PubMed Web of Science ®Google Scholar
• Ito D, Hatano M, Suzuki N. RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Sci Transl Med. 2017;9:eaah5436.
   Web of Science ®Google Scholar
• Yu S, Liang Y, Palacino J, et al. Drugging unconventional targets: insights from Huntington’s disease. Trends Pharmacol Sci. 2014;35:53–62.
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92–97.
   PubMed Web of Science ®Google Scholar
• Wu C, Jin X, Tsueng G, et al. BioGPS: building your own mash-up of gene annotations and expression profiles. Nucleic Acids Res. 2016;44:D313–316.
   PubMed Web of Science ®Google Scholar
• Trettel F, Rigamonti D, Hilditch-Maguire P, et al. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet. 2000;9:2799–2809.
   PubMed Web of Science ®Google Scholar
• Peng SS, Chen CY, Xu N, et al. RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. Embo J. 1998;17:3461–3470.
   PubMed Web of Science ®Google Scholar
• Ke Y, Han Y, Guo X, et al. PARP1 promotes gene expression at the post-transcriptiona level by modulating the RNA-binding protein HuR. Nat Commun. 2017;8:14632.
   PubMed Web of Science ®Google Scholar
• Fan XC, Steitz JA. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. Embo J. 1998;17:3448–3460.
   PubMed Web of Science ®Google Scholar
• Fan XC, Steitz JA. HNS, a nuclear-cytoplasmic shuttling sequence in HuR. Proc Natl Acad Sci U S A. 1998;95:15293–15298.
   PubMed Web of Science ®Google Scholar
• Yu M, Fu Y, Liang Y, et al. Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington’s disease models. Cell Res. 2017;27:1441–1465.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Moser R, Regulier E, et al. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington’s disease via additive effects of JNK and p38 inhibition. J Neurosci. 2013;33:2313–2325.
   PubMed Web of Science ®Google Scholar
• Joassard OR, Belanger G, Karmouch J, et al. HuR mediates changes in the stability of AChR beta-subunit mRNAs after skeletal muscle denervation. J Neurosci. 2015;35:10949–10962.
   PubMed Web of Science ®Google Scholar
• Xiao L, Li X, Chung HK, et al. RNA-binding protein HuR regulates paneth cell function by altering membrane localization of TLR2 via posttranscriptional control of CNPY3. Gastroenterology. 2019;157:731–743.
   Web of Science ®Google Scholar
• Jain A, Vale RD. RNA phase transitions in repeat expansion disorders. Nature. 2017;546:243–247.
   PubMed Web of Science ®Google Scholar
• Swami M, Hendricks AE, Gillis T, et al. Somatic expansion of the Huntington’s disease CAG repeat in the brain is associated with an earlier age of disease onset. Hum Mol Genet. 2009;18:3039–3047.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington’s disease. Neuron. 2019;102:899.
   PubMed Web of Science ®Google Scholar
• Genetic Modifiers of Huntington’s Disease Consortium. Electronic address, g.h.m.h.e. and Genetic Modifiers of Huntington’s Disease, C. CAG repeat not polyglutamine length determines timing of Huntington’s disease onset. Cell. 2019;178:887–900 e814.
   PubMed Web of Science ®Google Scholar
• Frantz B, Klatt T, Pang M, et al. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry. 1998;37:13846–13853.
   PubMed Web of Science ®Google Scholar
• Lang M, Berry D, Passecker K, et al. HuR small-molecule inhibitor elicits differential effects in adenomatosis polyposis and colorectal carcinogenesis. Cancer Res. 2017;77:2424–2438.
   PubMed Web of Science ®Google Scholar
• Saudou F, Humbert S. The biology of Huntingtin. Neuron. 2016;89:910–926.
   PubMed Web of Science ®Google Scholar
• Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89:867–882.
   PubMed Web of Science ®Google Scholar
• Buren C, Wang L, Smith-Dijak A, et al. Region-specific pro-survival signaling and global neuronal protection by wild-type Huntingtin. J Huntingtons Dis. 2014;3:365–376.
   PubMedGoogle Scholar
• Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle. 2006;5:824–828.
   PubMed Web of Science ®Google Scholar
• Zeitlin S, Liu JP, Chapman DL, et al. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat Genet. 1995;11:155–163.
   PubMed Web of Science ®Google Scholar
• Nasir J, Floresco SB, O’Kusky JR, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell. 1995;81:811–823.
   PubMed Web of Science ®Google Scholar
• Lu B, Al-Ramahi I, Valencia A, et al. Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance. Nat Neurosci. 2013;16:562–570.
   PubMed Web of Science ®Google Scholar
• Tollervey JR, Curk T, Rogelj B, et al. Characterizing the RNA targets and position-dependent splicing regulation by TDP-43. Nat Neurosci. 2011;14:452–458.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Wildenhain J, Rappsilber J, Tyers M. Boxplotr: a web tool for generation of box plots. Nature Methods. 2014;11:121–122. DOI: 10.1038/nmeth.2811
   PubMed Web of Science ®Google Scholar